FR
Centre de recherche
Azrieli du CHU Sainte-Justine
Hospital & care
Learning centre
Research
Rehabilitation
Health Promotion
Foundation
Centre de recherche
Azrieli du CHU Sainte-Justine
Search for:
Home
About Us
Research
Services
Core Facilities
Students
Media
Contact Us
Research
Research
Researchers
Associate Researchers
Research Axes
Research Chairs
Recruitment - Research projects
Clinical Research Units
Funding opportunities
Researcher
Noël J-M Raynal , M.Sc. , Ph.D.
noel.raynal@umontreal.ca
Research Axis
Immune Diseases and Cancer Axis
Research Theme
Cancers: mechanisms, new therapeutic approaches and disease outcomes
Address
CHUSJ
Phone
514 345-4931 #6763
Phone
#6763
Title
Associate Professor,
Department of Pharmacology and Physiology
, Université de Montréal
Principal investigator, CHU Sainte-Justine Research Center
Director of drug screening platform, CHU Sainte-Justine Research Center
Education
Postdoctoral training, MD Anderson Cancer Center, Department of Leukemia, University of Texas and Fels Institute for Cancer Research and Molecular Biology, Temple University (2009-2013)
Ph.D. in Biology, INRS-Institut Armand-Frappier, Université du Québec (2003-2008)
M.Sc. in Biology, Université du Québec à Montréal (2001-2003)
Undergraduate studies in Biochemistry, Université de Montpellier (2000)
Lab research interests
Epigenetic therapy of pediatric cancers
Epigenetic drug screening
3D cell culture
Lab members
Mariya Kryvoshey, Master's Student
Emmanuel Sy, Master's Student
Walid Mardhy, Master's Student
Anaïs Darracq, Postdoctoral Fellow
Marielle Huot, Research Assistant
Nicolas Sgarioto, Research Assistant
Publications
Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells. Huot M, Caron M, Richer C, Djibo R, Najmanovich R, St-Onge P, Sinnett D,
Raynal NJM
. Cancer Chemother Pharmacol. 2021 Jul 31.
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells. Dominici C, Sgarioto N, Yu Z, Sesma-Sanz L, Masson JY, Richard S,
Raynal NJ
. Clin Epigenetics. 2021 Mar 10;13(1):54.
Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation. Da Costa EM, Armaos G, McInnes G, Beaudry A, Moquin-Beaudry G, Bertrand-Lehouillier V, Caron M, Richer C, St-Onge P, Johnson JR, Krogan N, Sai Y, Downey M, Rafei M, Boileau M, Eppert K, Flores-Díaz E, Haman A, Hoang T, Sinnett D, Beauséjour C, McGraw S, R
aynal NJ
. J Exp Clin Cancer Res. 2019 Jun 13;38(1):251
TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity. Abusarah J, Cui Y, El-Hachem N, El-Kadiry AE, Hammond-Martel I, Wurtele H, Beaudry A,
Raynal NJ
, Robert F, Pelletier J, Jankovic M, Mercier F, Kamyabiazar S, Annabi B, Rafei M. Mol Cancer Ther. 2021 Jan;20(1):37-49.
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, Bhanu NV, Simithy J, Patel B, Huang J,
Raynal NJ
, Garcia BA, Jacobson MA, Kadoch C, Merali S, Zhang Y, Childers W, Abou-Gharbia M, Karanicolas J, Baylin SB, Zahnow CA, Jelinek J, Graña X, Issa JJ. Cell. 2018 Nov 15;175(5):1244-1258.e26.
DNA Methylation-Targeted Drugs. Da Costa EM, McInnes G, Beaudry A,
Raynal NJ
. Cancer J. 2017 Sep/Oct;23(5):270-276.
Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
Raynal NJ
, Da Costa EM, Lee JT, Gharibyan V, Ahmed S, Zhang H, Sato T, Malouf GG, Issa JJ. Mol Cancer Ther. 2017 Feb;16(2):397-407
Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.
Raynal NJ
, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, Andrews AJ, Jelinek J, Cui Y, Baylin SB, Gill DL, Issa JP. Cancer Res. 2016 Mar 15;76(6):1494-505.
Updated on 8/17/2021